Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | SNCA | P37840 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 3/20 | 0.36 |
| ▸ | CA2 | P00918 | 3/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 2/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | MMP1 | P03956 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | MMP8 | P22894 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20446605 | 0.81 | CA1 (0.42) | CYP2D6ALDH1A1LMNAHTTKDM4E | |
| SCHEMBL5740867 | 0.80 | CYP2D6 (0.48) | CYP2D6ALDH1A1LMNAHTTKDM4E | |
| SCHEMBL1026108 | 0.80 | CYP2D6 (0.39) | CYP2D6ALDH1A1LMNAHTTKDM4E | |
| SCHEMBL30728425 | 0.80 | CYP2D6 (0.39) | CYP2D6ALDH1A1LMNAHTTKDM4E | |
| SCHEMBL31424653 | 0.77 | CYP2D6 (0.43) | CYP2D6ALDH1A1LMNAHTTKDM4E | |
| SCHEMBL657897 | 0.77 | CYP2D6 (0.54) | CYP2D6ALDH1A1LMNAHTTKDM4E | |
| Phosphine SCHEMBL3185895 | 0.76 | GAA (0.59) | CYP2D6ALDH1A1LMNAHTTKDM4E | |
| SCHEMBL1541561 | 0.76 | CYP2D6 (0.50) | CYP2D6ALDH1A1LMNAHTTKDM4E | |
| SCHEMBL512305 | 0.75 | CYP2D6 (0.47) | CYP2D6ALDH1A1LMNAHTTKDM4E | |
| SCHEMBL5734726 | 0.75 | CYP2D6 (0.47) | CYP2D6ALDH1A1LMNAHTTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023070064-A1 | O-GLCNACASE (OGA) INHIBITOR COMBINATION THERAPY | ELI LILLY AND COMPANY (US) | 2023-04-27 | — | — | WO | disclosed |
| EP-3856739-A1 | 6-FLUORO-2-METHYLBENZO[D]THIAZOL-5-YL COMPOUNDS | Eli Lilly and Company (US) | 2021-08-04 | — | — | EP | disclosed |
| US-10836773-B1 | 6-fluoro-2-methylbenzo[d]thiazol-5-yl compounds | ELI LILLY AND COMPANY (US) | 2020-11-17 | — | — | US | disclosed |
| US-10752632-B2 | 6-fluoro 2-methylbenzo[d]thiazol-5-yl compounds | ELI LILLY AND COMPANY (US) | 2020-08-25 | — | — | US | disclosed |
| WO-2020068530-A1 | 6-FLUORO-2-METHYLBENZO[D]THIAZOL-5-YL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2020-04-02 | — | — | WO | disclosed |
| US-20200095254-A1 | 6-Fluoro-2-Methylbenzo[d]thiazol-5-yl Compounds | ELI LILLY AND COMPANY | 2020-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10752632-B2 | 6-fluoro 2-methylbenzo[d]thiazol-5-yl compounds | MAPT, HTT, TFEB | CYP2D6 601/4885ALDH1A1 712/4885LMNA 4522/4885 |
| US-20200095254-A1 | 6-Fluoro-2-Methylbenzo[d]thiazol-5-yl Compounds | MAPT, HTT, PSEN2 | CYP2D6 665/4885ALDH1A1 823/4885LMNA 4431/4885 |
| US-10836773-B1 | 6-fluoro-2-methylbenzo[d]thiazol-5-yl compounds | MAPT, HTT, PSEN2 | CYP2D6 665/4885ALDH1A1 823/4885LMNA 4431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.